纳武单抗诱发非小细胞肺癌患者哮喘发作 - Suppr

Nivolumab-induced asthma in a patient with non-small-cell lung cancer.

作者信息

Maeno K, Fukuda S, Oguri T, Niimi A

机构信息

Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

Ann Oncol. 2017 Nov 1;28(11):2891. doi: 10.1093/annonc/mdx455.

DOI:10.1093/annonc/mdx455

PMID:28945837

Abstract

摘要

相似文献

Nivolumab-induced asthma in a patient with non-small-cell lung cancer.

Ann Oncol. 2017 Nov 1;28(11):2891. doi: 10.1093/annonc/mdx455.

Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.

Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?

Cancer. 2018 Jul 15;124(14):2878-2880. doi: 10.1002/cncr.31557. Epub 2018 Jun 15.

HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors.

Cancer Sci. 2020 Sep;111(9):3395-3396. doi: 10.1111/cas.14536. Epub 2020 Jul 18.

Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer: promise, controversies and ambiguities in the novel treatment paradigm.

Scand J Clin Lab Invest. 2020 Sep;80(5):360-369. doi: 10.1080/00365513.2020.1742369. Epub 2020 Apr 2.

New onset of psoriasis during nivolumab treatment for lung cancer.

J Dermatol. 2018 Mar;45(3):e55-e56. doi: 10.1111/1346-8138.14167. Epub 2017 Dec 4.

Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.

Oncol Res Treat. 2017;40(10):621-622. doi: 10.1159/000477968. Epub 2017 Sep 19.

Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.

Eur J Cancer. 2019 Jul;115:107-110. doi: 10.1016/j.ejca.2019.04.022. Epub 2019 May 24.

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860.

引用本文的文献

Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review.

Front Immunol. 2025 Jul 22;16:1615531. doi: 10.3389/fimmu.2025.1615531. eCollection 2025.

Review of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment.

Biomedicines. 2024 Aug 19;12(8):1886. doi: 10.3390/biomedicines12081886.

Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report.

Respir Med Case Rep. 2024 Apr 30;49:102035. doi: 10.1016/j.rmcr.2024.102035. eCollection 2024.

The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.

Front Immunol. 2024 Feb 29;15:1333850. doi: 10.3389/fimmu.2024.1333850. eCollection 2024.

Immune checkpoint inhibitor-induced asthma and chronic obstructive pulmonary disease overlap in patient with adenocarcinoma.

Respirol Case Rep. 2023 Sep 19;11(10):e01222. doi: 10.1002/rcr2.1222. eCollection 2023 Oct.

Opportunistic Infections and Immune-Related Adverse Events Associated with Administering Immune Checkpoint Inhibitors: A Narrative Review.

Pharmaceuticals (Basel). 2023 Aug 9;16(8):1119. doi: 10.3390/ph16081119.

Therapeutic properties of Helicobacter pylori-derived vacuolating cytotoxin A in an animal model of chronic allergic airway disease.

Respir Res. 2023 Jul 6;24(1):178. doi: 10.1186/s12931-023-02484-5.

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature.

J Immunother Precis Oncol. 2023 Mar 21;6(2):111-116. doi: 10.36401/JIPO-22-30. eCollection 2023 May.

Immune checkpoint molecules in prevention and development of asthma.

Front Immunol. 2023 Feb 14;14:1070779. doi: 10.3389/fimmu.2023.1070779. eCollection 2023.

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.

Front Oncol. 2022 Aug 19;12:941079. doi: 10.3389/fonc.2022.941079. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Nivolumab-induced asthma in a patient with non-small-cell lung cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Nivolumab-induced asthma in a patient with non-small-cell lung cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献